NCT03346252View on ClinicalTrials.gov

The Effect of Botulinum Toxin A on Headache Attributed to TMD

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

March 15, 2021

Study Completion Date

March 15, 2021

Conditions
Secondary Headache Disorder
Interventions
DRUG

Botulinum Toxin type A

"All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.~In addition, they will undergo 3 cycles of treatment, each 12 weeks apart."

Trial Locations (1)

14214

University at Buffalo, Buffalo

All Listed Sponsors
lead

State University of New York at Buffalo

OTHER

NCT03346252 - The Effect of Botulinum Toxin A on Headache Attributed to TMD | Biotech Hunter | Biotech Hunter